G.F.R. More recently it has been shown that an infusion of a hypertonic solution of 1-arginine hydrochloride may restore mercury responsiveness (Gidekel et al. 1960 ). The reason is obscure, since neither the acidosis nor the increase in plasma chloride produced is great. This may prove a valuable measure in hepatic cirrhosis where ammonium chloride should not be given. The action of acetazolamide is soon limited by the metabolic acidosis which it produces.
The localization of the sites of action of various diuretic agents, partly made possible by the stopflow technique, has made the intelligent use of combinations of diuretics possible. It seems probable that a great deal of the sodium reabsorption that occurs when the G.F.R. is low takes place high up in the proximal tubule. Increasing the G.F.R. by intravenous aminophylline, or increasing proximal tubular flow by infusing mannitol, will bring more filtrate to the site of action of mercurials or chlorothiazide, whose effects will be enhanced. Moreover, since these agents affect different transport systems, their actions too may be synergistic when given together. The effect of a much greater load of sodium arriving distally at the site for ion-exchange may then result in a greatly increased output of potassium, when the addition of a spirolactone may be effective, countering the action of aldosterone at this site. These examples indicate the value of biochemistry in helping the treatment of resistant cases. It is not necessary to be able to estimate the urinary aldosterone in order to treat congestive failure effectively. But an interested physician, who studies not only the changes in plasma electrolyte levels but collects urine passed by patients who have received diuretics with an unsatisfactory response to discover the reason for this, will get very much better results in the long run than one who does not. The Renal Action of Chlorothiazide by A G Spencer GM MRCP (London) In many aspects of medicine discussion expands to fill the space made available by lack of data. Such is not the position with diuretics. During the past five years some twenty new diuretics have been introduced and more than two thousand papers have been published describing their use. Some of these represent a distinct advance in our therapeutic knowledge, while others merely extol the allegedly superior virtues of the latest drug. As with other potent drugs the thiazides may produce undesirable and occasionally disastrous side-effects, and it is the mechanism of these complications which I shall discuss. Benzothiazide diuretics work mainly by inhibiting those enzyme systems in the renal tubules which are concerned with the transport of ions. Glomerular filtration is also reduced. This is an example of the common therapeutic paradox of a drug which improves the patient's condition by making him worse, in the sense that a highly specialized physiological process is deliberately impaired by an even more specific pharmacological action. The formation of the glomerular filtrate is dependent on energy supplied by the contraction of the heart and transferred to the kidney by the blood stream. This is the purpose of the normal high renal blood flow of some 1,200 ml/min. Thiazide diuretics reduce the glomerular filtration rate (G.F.R.). This would result in a profound antidiuresis were it not for the action of thiazides on the renal tubules.
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The intravenous administration of chlorothiazide in the dog usually results in a 20% reduction of the inulin clearance or G.F.R., with little change in the CPAH or the estimated renal plasma flow ( Table 1) . Notice that the clearance of chlorothiazide greatly exceeds the filtration rate, indicating the tubular secretion of this drug. Intravenous chlorothiazide (500 mg) produces a similar fall in the G.F.R. in man (Fig 1) . This occurs before there is any considerable loss of water and electrolytes in the urine, and it is not due to a reduction in plasma volume. There is only a small fall in the renal blood flow. In this hypertensive patient there was a marked reduction in the filtration fraction (F.F.) from 0X26 to 0-15. This represents a decrease in the renal vascular resistance, the cause of which is unknown. It may be due to a direct action of the drug on the renal arterioles, to a decrease in the sodium content of the muscle in the renal vessels, or possibly to a reduction in the interstitial pressure ofthe kidney consequent on a loss of sodium from the tubular cells. It is probably a local expression of a general action of thiazides on small blood vessels, since it has recently been shown that chlorothiazides reduce the total peripheral vascular resistance.
It is important for the physician to be aware of the fall in the G.F.R. which may be produced by this group of diuretics. While in many patients this action is small and of no consequence, in others it may be relatively large, especially in subjects whose renal function is already impaired by disease. Substances which are mainly excreted by glomerular filtrationi.e. those for which tubular secretion is unimportantmay then accumulate in the body, for example urea, uric acid, antibiotics such as streptomycin, and many drugs.
In one hypertensive patient (Fig 2) the administration of 1 g of chlorothiazide a day for seven days resulted in a fall in the G.F.R. from 40 to 22 ml/min and the blood urea rose from 90 to over 200 mg/l00 ml. There was a fall in the blood pressure and in the plasma volume as measured with "31I-iodinated albumin. This upset was reversed by withdrawing the drug and giving extra salt. Cocoran et al. (1959) have reported a similar experience. The effects of pro-longed treatment with chlorothiazide resemble those produced by the rice diet. Healey et al. (1959) have found that benzothiazide diuretics reduce the excretion of urates. There is an elevation in the serum uric acid, and an acute attack of gout may occur. This is a complex action, partly due to the lowered G.F.R. and filtered load of urates and in part due to a reduction in the renal tubular secretion of this ion.
There is one group of patients in whom this fall in G.F.R. may be of therapeutic benefit, those with nephrogenic diabetes insipidus. In diabetes insipidus prolonged administration of thiazide diuretics results in a 50% reduction of the daily volume of urine. The mechanism of this antidiuresis is disputed (Crawford et al. 1960 ). Havard and Wood (1960) have demonstrated that it is accompanied by a 30-50% fall in the G.F.R. Both the antidiuretic action and the decrease in G.F.R. are reversed by giving salt. Tubular transport: The action of the thiazide drugs on the renal tubules may be investigated by clearance studies, by experiments on metabolizing kidney slices and by stop-flow analysis. These have been fully described and illustrated in the Proceedings (Spencer 1960) and elsewhere (Spencer 1959) .
The inhibition of the tubular reabsorption of sodium chloride results in an osmotic diuresis and consequent relief of cedema. The increased loss of potassium in the urine produced by thiazide diuretics may produce hypokalemia and extracellular alkalosis. This is particularly unfortunate since these drugs are most widely used in patients who already have a potassium deficiency state, namely in heart failure, hepatic cirrhosis, the nephrotic syndromes, severe hypertension, small intestinal disease and steroid-induced cedema. There is little convincing evidence that the more recently introduced thiazides, hydroflumethiazide (Blagg 1959 , Edmonds & Wilson 1959 and bendrofluazide and the allied drug chlorothiazide (Hygroton) cause a smaller loss of potassium in the urine.
The main hazards of potassium deficiency are sensitization to digitalis, hepatic coma, muscular weakness and paralysis and hypokalkmic nephropathy. An effective remedy is to give potassium chloride 1 g t.d.s. during thiazide treatment. An alternative is the combined use of thiazides and aldosterone antagonists.
A further serious hazard of thiazide treatment results from the inhibition of distal tubular hydrogen ion secretion. A rise in urine pH decreases the rate of excretion by non-ionic diffusion of weak organic bases such as mecamylamine and pempidine. The accumulation of hypotensive drugs may produce an excessive fall in blood pressure, a further reduction in G.F.R. and renal failure. Combined therapy with chlorothiazide, a ganglion blocker and digitalis is not rarely fatal. Since the uraemic patient cannot excrete these drugs the condition is self-perpetuating. In our experience treatment by hemodialysis has been successful; it simultaneously removes the drugs, corrects the urTmia and the hypokakEmia.
The Clinical Application ofAldosterone Antagonists inthe Treatment ofCEdema by Stanley Shaldon MB MRCP (London)
The synthesis of the steroidal-1 7-spirolactone compounds with marked aldosterone antagonist properties (Cella & Kagawa 1957 , Liddle 1958 , Slater et al. 1959 ) has provided the most potent diuretic for the treatment of cedematous states associated with secondary hyperaldosteronism. Cirrhotic patients with fluid retention secrete more aldosterone than cedematous patients with other diseases (Ulick 1959) . This communication deals with the use of the oral aldosterone antagonist, spironolactone (Aldactone, SC9420) in the treatment of patients with cirrhosis and ascites.
Clinical trials with an earlier intramuscular spirolactone, SC8109 (Kerr et al. 1958 ) were disappointing. Schedl & Bartter (1958) suggested that there was excessive proximal tubular reabsorption of sodium in cirrhotic patients with ascites and it was subsequently postulated that this mechanism was responsible for the failure of aldosterone antagonists to promote a sodium diuresis if used alone. It was suggested also that the combination of spironolactone with a proximal tubular diuretic of the thiazide series might produce a synergistic effect with a satisfactory sodium diuresis (Shaldon et al. 1960) (Fig 1) . Evidence in support of this hypothesis was obtained by studying the effect of chlorothiazide and spironolactone, given alone and in combination, to 9 patients with cirrhosis and resistant ascites (Fig 2) . All patients were resistant to chlorothiazide given alone, 2 patients experienced a small sodium diuresis and weight loss with spironolactone alone, but all patients showed a weightlosing sodium diuresis when the two diuretics were combined.
However, not all patients with cirrhosis and fluid retention require combined diuretic therapy.
In the past eighteen months, since sufficient spironolactone has been available for clinical trial, 51 patients with cirrhosis and fluid retention have required some form ofdiuretic therapy. This group does not include patients in whom fluid retention was a terminal manifestation of liver failure, or a transient state following a hemorrhage or operation. The patients were all treated at first with thiazide or mercurial diuretics, potassium supplements and a low salt diet. 33 patients (65 %) responded to this regime but 18 (350%) required spironolactone in addition. Only 4 patients (8 %) failed to achieve a satisfactory diuresis, and these 4 patients subsequently died of liver failure. Thus, approximately two-thirds of patients with cirrhosis and ascites or peripheral cedema may be adequately controlled with thiazide or mercurial diuretics and potassium alone, but all patients require a rigidly salt-restricted diet. Diuretic therapy is secondary to salt restriction.
I have studied recently a patient who was said to be resistant to chlorothiazide and spironolactone, but she was receiving an unrestricted salt intake. When put on a fairly low sodium diet she lost 2 kg in weight and subsequently her ascites was completely eliminated with chlorothiazide and potassium. Occasionally a patient will sbow an initially dramatic response to thiazide but then reaccumulate fluid in spite of continued therapy (Fig 3) . The occasional cirrhotic patient retains sodium so avidly that he is resistant to thiazides or mercurial diuretics from the onset of treatment. Under these circumstances spironolactone is indicated.
